Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma
Official title: A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma (MAPPING-ACC)
Run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT07507578 · Data updated 2026-11-12
We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 114 (estimated) |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | April 30, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07507578 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with pathologically confirmed primary ACC of the head and neck who have unequivocal distant metastases and can provide tumor tissue and blood samples and comply with study procedures.
✕Probably not a fit
Patients without distant metastases, with primary ACC outside the head and neck, or those lacking sufficient tissue or prior clinical data are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project applies multi-omics profiling (tumor genomics, transcriptomics, and blood-based biomarkers) to tumors and matched metastases from people with metastatic head and neck adenoid cystic carcinoma (ACC). Investigators will compare primary tumor biology to metastatic lesions and link molecular findings to published clinical risk groups derived from a nomogram. The study will also examine whether tumor biological type varies by metastatic site or timing and whether circulating biomarkers (including cell-free DNA and small RNAs) reflect tumor biology and treatment response. All procedures are correlative and samples are collected alongside standard-of-care treatments.
Why it matters
Potential benefit: If successful, the findings could help predict disease course and guide more personalized treatment and monitoring for people with metastatic head and neck ACC.
How similar studies have gone: Previous research has identified molecular subtypes in ACC and multi-omics approaches have shown promise in cancer profiling, but applying these methods specifically to progression patterns in metastatic head and neck ACC is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologic diagnosis of ACC * Primary ACC arising from the head and neck * Unequivocal clinical and/or radiological evidence of metastatic disease * Patient ability and availability to comply with study protocol procedures. Exclusion Criteria: * ACC patients with local and/or regional recurrence without distant metastases * Primary ACC arising from any non-head and neck region (e.g., breast, lung, skin etc) * Insufficient data about previous medical history.
Where it's running
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy Recruiting
Study contacts
- Principal investigator: Lisa Licitra — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study coordinator: Lisa Licitra
- Email: lisa.licitra@istitutotumori.mi.it
- Phone: +39 02 2390 2810
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First‑in‑human test of JBI-778 in lung cancer, glioma, and salivary gland cancers
This early-phase study tests whether the oral drug JBI-778 is safe and shows activity in adults with EGFR-mutated NSCLC, IDH-mutant glioma, or adenoid cystic carcinoma that has spread or is advanced.
-
Implantable microdevice drug screening for salivary and head and neck cancers
This will test whether a tiny implantable microdevice can safely and quickly deliver and screen multiple cancer drugs inside salivary gland and other head and neck tumors in patients scheduled for surgical removal.
-
Docetaxel and SX-682 in head and neck cancers and prostate cancer
This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.
-
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
This study tests how well patients with T4 sinonasal adenoid cystic carcinoma tolerate the standard treatment of surgery followed by postoperative radiotherapy and what their 3-year progression-free survival looks like.
-
Neoadjuvant therapy with anlotinib and epirubicin for T4 sinonasal adenoid cystic carcinoma
This trial tests whether giving a targeted drug (anlotinib) plus chemotherapy (epirubicin) before surgery helps patients with advanced sinonasal adenoid cystic carcinoma see better outcomes.
-
Surgery Alone or with Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
This study tests whether watching closely after surgery is as safe as adding postoperative radiotherapy for adults with completely removed (R0) early-stage sinonasal adenoid cystic carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.